BioCentury
ARTICLE | Company News

Context acquires onapristone from Arno

January 19, 2018 5:02 AM UTC

Cancer company Context Therapeutics (Philadelphia, Pa.) acquired worldwide rights to Apristor onapristone XR from Arno Therapeutics Inc. (Flemington, N.J.) for an undisclosed one-time payment. In December, Arno announced that it would dissolve and turn over Apristor to Context.

Context EVP and CFO Richard Morris told BioCentury that the company plans to start at least two Phase II trials by mid-2019 to evaluate Apristor as monotherapy or in combination with standard-of-care in patients with progesterone receptor-positive metastatic breast cancer...